Cancer Research UK and Cancer Research Technology are to join forces with big pharma, Astellas Pharma to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.
Cancer Research UK, CRT and Astellas will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.
The first stage aims to identify and then validate the best possible drug targets to block the autophagy pathway in pancreatic cancer cells.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Astellas
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity